Zynerba Press Releases

23 May 23 Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

15 May 23 Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights

12 Apr 23 Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg Conference

5 Apr 23 Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference

28 Mar 23 Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

13 Mar 23 Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank

7 Mar 23 Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

1 Mar 23 Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference

11 Jan 23 Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome

21 Dec 22 Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome